Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Advertisement
Articles by Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator, Hematology/Oncology, The University of Arizona Cancer Center, clinical assistant professor, The University of Arizona College of Pharmacy, discusses the regulatory pathway for biosimilars in oncology.
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses factors that need to be taken into consideration as biosimilars emerge in oncology.
Advertisement
Latest Updated Articles
Dr. McBride on the Emergence of Biosimilars in OncologyNovember 26th 2019
Dr. McBride on the Regulatory Pathway for Biosimilars in OncologyDecember 2nd 2019
Dr. McBride on the Potential of Biosimilars in OncologyDecember 4th 2019
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5